COVID-19 Drug design and Development
COVID-19 medicate advancement is the inquire about handle to create preventative helpful medicine drugs that would reduce the seriousness of coronavirus illness 2019 (COVID-19). From early 2020 through 2021, a few hundred medicate companies, biotechnology firms, college investigate bunches, and wellbeing organizations were creating restorative candidates for COVID-19 infection in different stages of preclinical or clinical investigate (506 add up to candidates in April 2021), with 419 potential COVID-19 drugs in clinical trials, as of April 2021.
Related Conference of COVID-19 Drug design and Development
March 09-10, 2026
21th International Conference on Allergic Diseases and Clinical Immunology
Singapore City, Singapore
April 16-17, 2026
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
London, UK
COVID-19 Drug design and Development Conference Speakers
Recommended Sessions
- Cardiac manifestations of coronavirus
- Coronaviruses (COVID-19)
- COVID-19 and Environmental Health
- COVID-19 Clinical Trails
- COVID-19 Drug design and Development
- Epidemiological Characteristics of COVID-19
- Food and Nutrition
- Genomics and transmissibility
- Infectious Diseases Covid-19
- Mental health
- Monoclonal antibody treatments
- Omicron
- SARS-CoV-2 variants
- Severe Acute Respiratory Syndrome Coronavirus 2
- Therapeutics and COVID-19
- Vaccines
- Virology
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Cancer Immunology and Immunotherapy - European Immunology 2025 (Italy)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Diagnostic and Technological Novelty of Immunology - European Immunology 2025 (Italy)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Epidemiology - European Immunology 2025 (Italy)
- Immune System - European Immunology 2025 (Italy)
- Immunodeficiency - European Immunology 2025 (Italy)
- Immunogenetics - European Immunology 2025 (Italy)
- Immunoinformatics & Systems Immunology - European Immunology 2025 (Italy)
- Immunological Techniques - European Immunology 2025 (Italy)
- Immunology - European Immunology 2025 (Italy)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Immunotherapy - European Immunology 2025 (Italy)
- Immunotoxicology - European Immunology 2025 (Italy)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Neuroimmunology - European Immunology 2025 (Italy)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Parasite Immunology - European Immunology 2025 (Italy)
- Pediatrics Immunology - European Immunology 2025 (Italy)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- Reproductive Immunology - European Immunology 2025 (Italy)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
- Transplantation Immunology - European Immunology 2025 (Italy)
- Viral Immunology - European Immunology 2025 (Italy)